克罗恩病诊断延迟的危险因素及其对长期并发症的影响:在结核病流行地区有何不同
在印度结核病流行区,基于前瞻性炎症性肠病登记库回顾性分析720例克罗恩病患者,诊断延迟>18个月者狭窄并发症和手术风险显著增高,经验性抗结核治疗是诊断延迟的最大单一因素,且即使初期有临床应答,长期狭窄并发症仍更高。
要点
- 诊断延迟>18个月与狭窄并发症(OR 4.12)和需手术(OR 2.41)风险显著增高相关。
- 经验性抗结核治疗显著延长诊断延迟(OR 2.47),是结核流行区诊断延迟的最大单一因素。
- 接受过抗结核治疗者狭窄并发症发生率显著更高(28.49% vs 14.8%,OR 2.60)。
核心结论
- 克罗恩病诊断延迟与显著更高的狭窄并发症和需手术相关。
- 经验性抗结核治疗是结核病流行地区诊断延迟的最大单一因素。
- 尽管对经验性抗结核治疗初期有临床应答,长期狭窄并发症仍更高。
研究设计与样本
- 回顾性分析来自大型前瞻性建立的炎症性肠病登记库的数据。
- 共纳入720例克罗恩病患者,男性占60.3%,中位年龄28岁。
- 从症状出现到诊断的时间定义为诊断延迟,按中位诊断延迟分为两组。
- 采用逻辑回归分析评估诊断延迟对狭窄和瘘管并发症及需手术的影响。
主要发现
- 诊断延迟>18个月(中位数)者较≤18个月者狭窄并发症显著更高(OR 4.12;95%CI:2.74-6.33,P<0.001)。
- 诊断延迟>18个月者较≤18个月者需手术显著更高(OR 2.41;95%CI:1.68-3.42,P<0.001)。
- 两组瘘管并发症发生无差异。
- 193/720(27%)接受抗结核治疗,显著促成诊断延迟(OR 2.47;95%CI:1.76-3.47,P<0.001),其中47%显示初始临床应答(克罗恩病活动指数CDAI下降>100)。
- 接受过抗结核治疗者狭窄并发症发生率显著高于未接受者(55/193(28.49%) vs 78/527(14.8%),P<0.001,OR 2.60,95%CI:1.64-4.12)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnosis of Crohn's disease (CD) can be delayed in clinical practice. In tuberculosis endemic areas, empirical anti-tubercular therapy further delays treatment. AIM(S): To assess risk factors for diagnostic delay and its impact on the long-term complications of Crohn's disease in India where tuberculosis is endemic. METHODS: Data from a large prospectively established inflammatory bowel disease registry were analysed retrospectively. The time from onset of symptoms to diagnosis (diagnostic delay) was calculated and categorised into two groups based on median diagnostic delay. The risk factors for delay including anti-tubercular therapy were analysed. Logistic regression analysis was done to assess impact of diagnostic delay on development of stenotic and fistular complications including need for surgery. RESULTS: Seven hundred and twenty Crohn's disease patients (60.3% male, median: 28 years) were included. Main outcome measures were stenosis, fistula and need for surgery. Subjects with diagnostic delay >18 months (median) developed significantly higher stenotic complications and surgery (OR 4.12; 95% CI: 2.74-6.33, P < 0.001 and OR 2.41, 95% CI: 1.68-3.42, P < 0.001), respectively, compared to those ≤18 months. There was no difference in the development of fistulous complications. 193/720 (27%) received anti-tubercular therapy which significantly contributed to diagnostic delay (OR: 2.47; 95% CI: 1.76-3.47, P < 0.001) with 47% showing initial clinical response (Crohn's disease activity index- CDAI decrease >100). Moreover, the incidence of stenotic complications was significantly higher in patients who had received prior anti-tubercular therapy (55/193 (28.49%) vs 78/527 (14.8%), P < 0.001, OR: 2.60, 95% CI: 1.64-4.12). CONCLUSIONS: Diagnostic delay in Crohn's disease is associated with significantly higher stenotic complications and need for surgery. Empirical anti-tubercular therapy is the single largest contributor to diagnostic delay in tuberculosis endemic areas. Despite initial clinical response to anti-tubercular therapy, long-term stenotic complications are higher.
引用
- Banerjee R, Pal P, Girish BG, et al. Risk factors for diagnostic delay in Crohn's disease and their impact on long-term complications: how do they differ in a tuberculosis endemic region? Aliment Pharmacol Ther. 2018. PMID: 29572889. doi:10.1111/apt.14617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。